31 results about "Neuronal apoptosis" patented technology

Provided is a polypeptide which contains a polypeptide having at least 80%, 85%, 90%, 95%, or 99% identity to amino acid sequence MTYRPGYNPFG (SEQ ID NO: 41) or amino acid sequence AKGYYRPYGVPV (SEQ ID NO: 22), or a polypeptide having one or more amino acid substitutions, deletions and / or additions relative to the amino acid sequence as shown in SEQ ID NO: 41 or 22. The provided polypeptide can interfere with the binding of a Brag2 synaptic protein to the C terminus of an AMPA receptor, thereby inhibiting NMDA-mediated excessive endocytosis of an AMPA receptor and neuronal apoptosis, and playing a role in protecting neuronal cell activity. Therefore, the polypeptide has application prospects and potential development values as a drug for treating nervous system diseases such as strokes, depression, Alzheimer's disease and drug addiction.

The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease, and belongs to the field of biopharmaceutical technology. The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease. By verifying the effects of Yangxue Oral Liquid on the amyloid beta-induced neuronal apoptosis model, the cobalt chloride-induced SH‑SY5Y cell hypoxia model, and the LPS-induced SH‑SY5Y cell inflammation model, the results showed that Yangxue Oral Liquid has a neuroprotective effect against Alzheimer's disease and / or Parkinson's disease. Therefore, the application provided by the present invention provides a new means for neuroprotection against Alzheimer's disease and / or Parkinson's disease.

The invention discloses a neuronal apoptosis risk assessment system based on an oxidative stress signal axis. The neuronal apoptosis risk assessment system comprises the following steps: acquiring oxidative stress biomarker measurement data; calculating an oxidative stress signal axis activation index based on the oxidative stress biomarker measurement data; determining a neuronal apoptosis key factor expression level based on the oxidative stress signal axis activation index; calculating a neuronal apoptosis risk assessment value based on the neuronal apoptosis key factor expression level; and outputting the neuronal apoptosis risk assessment value. Compared with the prior art, the neuron apoptosis risk assessment method has the following advantages and effects: on the basis of integrated analysis of the oxidative stress signal axis multi-level biomarkers, through dynamic weight adjustment and activation index quantification, more accurate and systematic assessment of the neuron apoptosis risk is realized, and the reliability of risk assessment in non-diagnostic research is remarkably improved.

The invention provides an engineered TAT and RVG dual-targeting peptide modified exosome loaded microRNA inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the engineered TAT and RVG peptide exosome, the exosome is extracted from a supernatant of an MSC cell culture medium, the DiR-labeled exosome, FITC-labeled CP05-TAT peptide and 5-TAMRA-labeled CP05-RVG peptide are mixed and incubated together, the TAT and RVG dual-targeting peptide modified exosome is obtained, a miR-15b-5p inhibitor is loaded through ultrasound, and Exo-TATamp loaded with the miR-15b-5p inhibitor is prepared; the TAT and the RVG are used for co-modifying the MSC-EXOs, so that blood-brain barrier penetration and neuronal targeting can be remarkably enhanced, the delivery effect of a microRNA-15b-5p inhibitor is enhanced, and the injury induced by cerebral ischemia reperfusion is relieved by inhibiting neuronal apoptosis.

This invention discloses a wearable targeted static magnetic field device and its usage method for early intervention in Alzheimer's disease, belonging to the field of physical therapy equipment technology. The device consists of a permanent magnet array, a metal shield, a magnet support device, and a support shell suitable for wearing on the head. The device generates a constant static magnetic field spatial distribution with multiple focal points and a specific gradient within the wearer's skull through the arranged permanent magnet array. The characteristic parameters of this distribution include: multiple local intensity peaks of 10-50 mT and a spatial gradient of 0.5-5 T / m. As an intervention method, the static magnetic field can significantly inhibit Tau protein LLPS, reduce neuronal apoptosis, and improve the patient's cognitive function. This invention is a soft, elastic, wearable device that provides a novel, precisely targeted, and easy-to-use physical therapy solution for AD.

The invention belongs to the technical field of drug delivery systems, and discloses multifunctional microalgae hydrogel as well as a preparation method and application thereof. According to the multifunctional microalgae hydrogel, natural components are taken as carriers, efficient release of drugs at the far end of the intestinal tract is achieved through pH and an intestinal flora enzyme response mechanism, the retention time of the far end of the intestinal tract is remarkably prolonged in combination with the adhesion characteristic, and the time-space distribution of the drugs is monitored in real time by supporting a fluorescent tracing technology. Meanwhile, by precisely regulating and controlling the homeostasis of intestinal flora, the intestinal barrier and the blood brain barrier are repaired, neuroinflammation, neuronal apoptosis and A beta deposition are remarkably improved, and cognitive impairment is reversed. The technical bottlenecks of poor targeting property and low bioavailability of a traditional oral preparation are broken through, a safe and efficient novel drug delivery strategy is provided for intervening neurodegenerative diseases based on the intestine-brain axis, and the preparation has remarkable clinical transformation potential and application value.

The invention provides a drug-loaded nano-microsphere for spinal cord injury recovery and application thereof, and relates to the technical field of biomedicine, the technical key point is that the drug-loaded nano-microsphere is provided, the drug-loaded nano-microsphere is characterized in that the drug-loaded nano-microsphere is prepared by an emulsified solvent evaporation method, a polymer and a drug are dissolved in an organic solvent, and the polymer and the drug are mixed uniformly to obtain a drug-loaded nano-microsphere solution; then emulsifying into a water phase, and finally, volatilizing an organic solvent to form microspheres; polyethylene glycol and a targeting ligand are added on the surface of a modified nano-microsphere, and the drug inhibits the SOCS3 / STAT pathway in a targeting manner. According to the research, a GM1-PLGA-PEG (at) FPR2 nano delivery system with a spinal cord targeting function is constructed, the system is good in slow release performance and high in biocompatibility, and neuronal apoptosis after H2O2 stimulation is effectively reduced. The drug-loaded nano-microspheres are used for simulating treatment of spinal cord injury, so that various movement functions and spinal cord health of rats with spinal cord injury can be improved, and the injured spinal cord can be targeted to promote neural restoration. The GM < 1 >-PLGA-PEG microspheres do not show strong liver retention, and show good biological safety in various tissues.

The present invention discloses the use of the TNFRSF1A inhibitor miR-3059-5p in the treatment of stroke. Examples of the present invention demonstrate that miR-3059-5p can inhibit neuronal apoptosis and parthanatos death induced by OGD / R by negatively regulating TNFRSF1A expression, thereby alleviating neuronal damage caused by OGD / R. Therefore, the research results of this invention provide a potential new drug for the clinical treatment of stroke.

The invention is applicable to the field of medicines, and particularly relates to a rhizoma cimicifugae-containing traditional Chinese medicine composition for treating Alzheimer's disease, which comprises the following components in parts by weight: 5-15 parts of rhizoma cimicifugae, 8-12 parts of ginseng, 10-15 parts of astragalus membranaceus, 6-10 parts of salvia miltiorrhiza, 4-8 parts of rhizoma acori graminei, 3-6 parts of polygala tenuifolia, 5-8 parts of spina date seed, 10-15 parts of poria cocos, 6-10 parts of radix ophiopogonis, 12-18 parts of oyster, 8-12 parts of concha haliotidis and 4-8 parts of gastrodia elata. The cimicifugae foetidae-containing traditional Chinese medicine composition for treating the Alzheimer's disease has the beneficial effects that the cognitive function is improved: the salvia miltiorrhiza, the rhizoma acori graminei and the polygala tenuifolia can promote cerebral blood perfusion, enhance synaptic plasticity and inhibit neuronal apoptosis; the rhizoma cimicifugae and the radix astragali are combined to improve brain microcirculation and reduce beta-amyloid protein aggregation, so that the learning and memory ability is remarkably improved.

Disclosed in the present invention are a tricyclic compound, a preparation method therefor and the use thereof. The tricyclic compound of the present invention are a tricyclic compound as shown in I', a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof. The tricyclic compound of the present invention is capable of protecting neurons, promoting repair of damaged neurons, inhibiting neuronal apoptosis, and slowing down AD cognitive decline, and have good pharmaceutical prospects.

Provided are molecules and compositions for eye-targeted gene therapy and methods of using the same. The eye-targeted gene therapy alleviates ischemic retinopathy by reducing pathologic neovascularization, gliosis and neuronal apoptosis.

The invention provides application of rosmarinic acid in treatment of cervical spondylotic myelopathy. Specifically, animal experiments and in-vitro cell experiments are carried out by constructing a rat cervical spondylotic myelopathy model, and it is verified that rosmarinic acid has a neuroprotective effect and can inhibit neuronal apoptosis under the conditions of ischemia and hypoxia. Experiments show that the rosmarinic acid can enhance mitochondrial autophagy by activating AMPK-TFEB and PINK1-PRKN signal pathways, so that neurons are protected from ischemia and hypoxia, and neuronal cell apoptosis is inhibited. Based on the invention, the rosmarinic acid or the derivative thereof can be used for preparing the medicine for treating cervical spondylotic myelopathy.

The invention discloses a new application of S-methyl-5-thioadenosine, and the S-methyl-5-thioadenosine can be used as a hepatic encephalopathy biomarker. The invention relates to application of S-methyl-5-thioadenosine, a pharmaceutically acceptable salt thereof and / or a prodrug thereof as an active ingredient in preparation of drugs for preventing and / or treating hepatic encephalopathy, MHE and neuroinflammation and application of S-methyl-5-thioadenosine, a pharmaceutically acceptable salt thereof and / or a prodrug thereof as an active ingredient in preparation of drugs for preventing and / or treating hepatic encephalopathy, MHE and neuroinflammation. The invention also relates to application in medicines for improving cognition. Clinical data, animal experiments and cell model researches find that MTA can effectively relieve neuroinflammatory response of MHE patients, inhibit neuronal apoptosis and improve cognition, so that learning and memory ability is improved, and the application prospect is wide.

The invention relates to the technical field of biological medicine and fundus disease treatment, in particular to application of Acbd3 in treatment of fundus diseases. In the retina of a fundus disease model mouse, the mRNA expression level and the protein expression level of Acbd3 are obviously increased relative to those of a control group. After the Acbd3 inhibitor is used, inflammatory response and neuronal apoptosis in the retina of the fundus disease model mouse are remarkably relieved, abnormal activation of Muller cells and microglial cells can be reduced, and the damaged blood-retina barrier can be repaired.

The present invention provides a milk casein hydrolyzate and its preparation method and application. The composition of the milk casein hydrolyzate of the present invention includes at least one of the peptide segment 1 with an amino acid sequence as shown in SEQ ID NO: 1, the peptide segment 2 with an amino acid sequence as shown in SEQ ID NO: 2, and the peptide segment 3 with an amino acid sequence as shown in SEQ ID NO: 3. The milk casein hydrolyzate has good neuronal protection and repair effects, can improve cholinergic neuron and dopaminergic neuron damage; can inhibit Aβ protein deposition, thereby alleviating neuronal synaptic disorders, neuronal apoptosis and brain damage caused by Aβ protein deposition; can improve cholinergic defects, thereby alleviating neurodevelopmental impairment, behavioral and motor disorders caused by cholinergic defects; can also repair damaged neurons in the hippocampus and hypothalamus, thereby maintaining a stable brain environment.

The invention provides application of XBP1 protein in preparation of a medicine for treating epilepsy, and relates to the technical field of biological medicine. In the pathophysiological process of epilepsy, X-box binding protein 1 (XBP1) serves as a key regulatory factor of endoplasmic reticulum stress and plays an important role, the XBP1 can regulate expression of endoplasmic reticulum stress related genes and inhibit neuronal apoptosis so as to influence the pathologic process of epilepsy, epilepsy is a chronic brain disease caused by multiple etiological factors, and the epilepsy is a chronic brain disease caused by multiple etiological factors. The invention develops an anti-epileptic drug based on a non-ionic channel as a target, and XBP1 is used as a beneficial supplement of the existing anti-epileptic drug and is beneficial to improving the effective rate of epileptic drug treatment on the whole.

The invention belongs to the technical field of traditional Chinese medicine preparation, and particularly relates to a medicine for treating cerebral arterial thrombosis, the medicine is prepared from the following raw materials in parts by weight: 10-15 parts of angelica sinensis, 6-10 parts of ligusticum wallichii, 10-15 parts of salvia miltiorrhiza, 6-10 parts of frankincense, 6-10 parts of myrrh, 3-6 parts of leech, 10-15 parts of centella asiatica and 10-15 parts of sculellaria barbata, experiments show that the medicine can effectively improve neurological functions; the cerebral infarction volume of the rat can be obviously reduced; in the aspect of brain tissue pathological damage, after the medicine is added for intervention, pathological changes such as nerve cell degeneration and necrosis occurring in a model group can be relieved to different degrees; under the condition of neuron apoptosis, the number of apoptotic cells of a model group is increased, and the medicine can reduce the number of apoptotic cells; in general, the medicine provided by the invention has a remarkable treatment effect on patients suffering from cerebral arterial thrombosis.

The invention belongs to the technical field of ischemic stroke treatment, and discloses application of ULK1 possibly serving as a target spot for treating ischemic stroke. According to the invention, a photothrombotic stroke model is established, a ULK1 inhibitor SBI-0206965 (SBI), LYN1604 hydrochloride (LYN) and a ULK1 agonist are administered, and the ULK1 agonist is used for regulating the activity of ULK1 in vivo. Examples assess the outcome of sensory motor deficits, neuronal apoptosis, and microglia / macrophage activated neurological function. Immunofluorescence detection results show that ULK1 is mainly located in microglial cells in a post-ischemic infarction area of China. Upregulated ULK1 is treated by LYN, so that the infarct volume is remarkably reduced, the motor function is improved, and the increase of inflammatory microglial cells is promoted. In conclusion, the ULK1 promotes the repair of neurons and promotes the formation of 13 paths of anti-inflammatory microglial cell paths after ischemic injury.

This invention provides an oligosaccharide composition for improving neurodevelopment and functional disorders, comprising 6'-sialyl lactose and lactose-N-trisaccharide. The oligosaccharide composition provided by this invention can effectively inhibit the accumulation of Aβ protein, which leads to neuronal synaptic disorders, neuronal apoptosis, brain damage, and functional disorders. Therefore, the oligosaccharide composition provided by this invention can protect nerves and improve functional disorders. Furthermore, the oligosaccharide composition provided by this invention can also inhibit acetylcholinesterase activity, protect the normal development of cholinergic neurons, and increase neurotransmitter levels, thus benefiting the improvement of neurodevelopment, learning and memory abilities, and the improvement of behavioral coordination in infants and young children.

The invention discloses ascophyllum nodosum fucoidin ANFS, a preparation method thereof and application of the ascophyllum nodosum fucoidin ANFS in preparation of a preparation for preventing and treating Alzheimer's disease, and belongs to the technical field of marine biological medicine. The main chain of the ascophyllum nodosum fucoidin ANFS is composed of alpha-L fucoidin residues connected with (1-> 3), and the branch chain is monosaccharide or sulfate group. Sulfating modification occurs at C-2 and C-4 sites of fucose residues, and the molecular weight of the fucose residues is 15-30 kDa. Experiments prove that ANFS can remarkably improve the movement behavior defect of zebrafish, inhibit the activity of acetylcholin esterase, improve the activity of catalase and glutathione peroxidase, reduce the level of active oxygen in cells, reduce brain neuron apoptosis and effectively protect the integrity of a blood brain barrier. The polysaccharide is rich in source, simple and convenient in preparation process and high in safety, and has a wide application prospect in the aspect of developing marine drugs and functional products for treating the Alzheimer's disease.

The invention relates to an antibody drug for preventing and treating sepsis-related encephalopathy and application thereof. Variable region complementary determining regions and full-length amino acid sequences of a heavy chain and a light chain of an antibody are clear. The sepsis-related encephalopathy is high in morbidity and mortality, existing treatment means are limited, and the core pathogenesis of sepsis-related encephalopathy is related to blood-brain barrier injury and neuroinflammation. The A-FABP antibody 6H2 is combined with A-FABP through high affinity, the integrity of a blood brain barrier is protected, neuronal apoptosis is inhibited, symptoms of sepsis-related encephalopathy are remarkably improved, a breakthrough solution from symptomatic treatment to cause treatment is provided for the sepsis-related encephalopathy, and the A-FABP antibody 6H2 has important clinical application value.

The invention provides a co-assembly of a macrocyclic amphiphilic compound and an MST1 inhibitor as well as a preparation method and application of the co-assembly, and relates to the technical field of medicines. The co-assembly of the macrocyclic amphiphilic compound and the MST1 inhibitor is prepared from the macrocyclic amphiphilic compound, the MST1 inhibitor and Angiopep-2, wherein the macrocyclic amphiphilic compound and the MST1 inhibitor are co-assembled with the Angiopep-2; wherein the macrocyclic amphiphilic compound comprises a co-assembly body of guanidyl modified calixarene and cyclodextrin. According to the co-assembly disclosed by the invention, the treatment effect of the co-assembly on the Alzheimer's disease is enhanced by improving pathological processes such as neuronal apoptosis, neuroinflammation, synaptic plasticity injury and cognitive impairment in the Alzheimer's disease, and the limitation that only A beta is eliminated in the prior art is improved; according to the present invention, with the application of the polypeptide, the depolymerization and the removal of the A beta plaque, the fiber body and the oligomer can be achieved, the A beta cytotoxicity can be significantly reduced, the nerve cell apoptosis and the synaptic injury can be reduced, the cognitive disorder can be improved, and the comprehensive treatment effect can be provided.

The invention discloses an application of luteolin in preparation of a medicine for improving cognitive impairment induced by corticosterone (Cort), and relates to a medicine for improving cognitive impairment induced by corticosterone (Cort). By constructing a mouse cognitive impairment model induced by chronic Cort, research proves that the luteolin can remarkably improve the spatial learning and memory ability of a model mouse. The action mechanism is related to a multi-target synergistic effect, and mainly comprises the steps of relieving oxidative stress injury, inhibiting hippocampal neuron apoptosis, adjusting the autophagy level and enhancing synaptic plasticity. The new application and multi-mechanism synergistic effect of the luteolin for improving the Cort-induced cognitive impairment are defined, and a new technical scheme is provided for developing safe and effective cognitive impairment treatment medicines.

The invention discloses puerarin lipidosome with ginsenoside Rh2 as a lipid membrane material and a preparation method and application of the puerarin lipidosome, the membrane material cholesterol of the lipidosome is replaced with the lipidosome (Rh2-Pue-LP) of ginsenoside Rh2 de-entrapped puerarin, the Rh2-Pue-LP can inhibit and activate a JAK2-STAT3 signal channel, so that transcription of NLRP3 is inhibited, and the lipidosome has the advantages that the lipidosome can be used for preparing the puerarin lipidosome with the ginsenoside Rh2 as the lipid membrane material; the traditional Chinese medicine composition can be used for inhibiting microglial cell activation and neuronal apoptosis, effectively penetrating through a complete blood brain barrier (BBB), reaching a focus part and playing a role in neuroprotection.

This invention belongs to the field of pharmaceutical technology. Addressing the lack of reported applications of Astragalus injection in the preparation of drugs for treating cerebral hemorrhage, this invention proposes the use of Astragalus injection in the preparation of drugs for treating cerebral hemorrhage. Experimental results show that Astragalus injection can protect brain tissue neurons by inhibiting the HMGB1 / RAGE signaling pathway, inhibiting neuronal apoptosis, and reducing the expression of inflammatory factors in brain tissue, thereby achieving a protective effect against cerebral hemorrhage in rats. Therefore, Astragalus injection has the potential to be used as a drug for treating cerebral hemorrhage.

The invention discloses application of a transcription factor EGR1 in preparation of a medicine for treating traumatic brain injury, and relates to the technical field of medicines. By integrating transcriptomics and epigenomics analysis, the invention reveals the effect of EGR1 in regulating and controlling the mitochondrial homeostasis through an HIF1alpha / BNIP3 axis after trauma. EGR1 is found to be a key regulatory factor of TBI pathology, and the expression of EGR1 shows acute up-regulation in injured neurons. After the EGR1 gene is knocked out from a mouse, the neuron apoptosis is obviously reduced. Chromatin immunoprecipitation and dual luciferase reporter gene experiments show that EGR1 is directly combined with an HIF1alpha promoter to inhibit transcription of the HIF1alpha promoter. The deletion of EGR1 can enhance mitochondrial autophagy mediated by HIF1 alpha / BNIP3, so that mitochondrial dysfunction and oxidative stress in in-vitro and in-vivo experiments are reduced. On the contrary, the nerve protection effect of EGR1 knockout can be eliminated by silencing the HIF1alpha or the BNIP3. The discovery determines that an EGR1-HIF1 alpha-mitochondrial autophagy signal axis is used as an important determinant of TBI prognosis, and indicates that EGR1 has potential therapeutic value.

This invention provides the application of metformin in the preparation of a drug for treating learning and memory deficits caused by schizophrenia with normal glucose and lipid metabolism, belonging to the field of pharmaceutical technology. This invention discovers that metformin, under conditions of normal glucose and lipid metabolism, can effectively reduce neuronal apoptosis and neuroinflammatory damage in the prefrontal cortex of the brain in schizophrenia patients, thereby improving their learning and memory deficits. This invention further provides that the molecular target of metformin in repairing prefrontal cortex damage in schizophrenia is CTSS, and that it can downregulate the expression level of CTSS in the prefrontal cortex. The metformin described in this invention represents a repurposing of an existing drug, shortening drug development time and costs, and providing an effective drug treatment for learning and memory deficits caused by schizophrenia with normal glucose and lipid metabolism.

This invention relates to the field of probiotics technology, specifically to the application of a particular strain of *Lactobacillus paracasei* in the preparation of a strain for the prevention, relief, or treatment of cognitive impairment and related mood disorders caused by chronic sleep deprivation. The *Lactobacillus paracasei* is... Lactobacillus paracasei BKR005. This invention's probiotic indirectly promotes endogenous butyrate production by reshaping the gut microbiota, and effectively inhibits neuroinflammation and neuronal apoptosis through its unique MCT1 repair function, providing a clear target and novel mechanism for intervening in neuropsychiatric damage driven by chronic sleep deprivation.

The invention discloses selenized astragalus polysaccharide hydrogel with Parkinson's disease treatment activity as well as a preparation method and application of the selenized astragalus polysaccharide hydrogel. The hydrogel is prepared by the following steps: (1) carrying out selenylation modification on astragalus polysaccharide and NaSeO under the reduction of ascorbic acid to obtain selenylated astragalus polysaccharide; and (2) mixing sodium alginate with the selenized astragalus polysaccharide solution, and performing ultrasonic emulsification and centrifugal purification to obtain the monodisperse nano hydrogel. The hydrogel has a three-dimensional network structure, can efficiently remove reactive oxygen free radicals, and inhibits MPP-induced neuronal apoptosis. The selenized astragalus polysaccharide hydrogel prepared through selenylation modification overcomes the problems that traditional hydrogel is insufficient in oxidation resistance and unstable in drug effect in the Parkinson's disease treatment process, and has the advantages of being definite in biological activity, excellent in oxidation resistance, good in biocompatibility and the like. The method is simple in process, low in consumption, environmentally friendly, green and efficient, has important theoretical significance and great clinical application value, and provides a novel, safe and efficient biological material strategy for treatment of Parkinson's disease.

The invention relates to a traditional Chinese medicine component compound. The traditional Chinese medicine component compound comprises baicalin, salidroside and catalpol. The traditional Chinese medicine component compound disclosed by the invention is a traditional Chinese medicine compound, pays attention to enhancement of an autoimmune system, and is free of toxic and side effects and reasonable in formula; the traditional Chinese medicine composition effectively aims at main pathogenesis of ischemic encephaledema and cerebral ischemia, such as reduction of cerebral moisture content, reduction of cerebral ischemia area, alleviation of neurological dysfunction, reduction of neuronal apoptosis and the like, and has a remarkable curative effect; the raw materials are wide in source and easy to obtain, can be extracted and biosynthesized by adopting crude drugs, can also be directly used as chemical synthesis products, and are convenient for preparation and large-scale production.